Galectin-9 in cancer therapy

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 2, 2013, Pages 130-137

  Fujihara, Shintaro ^a   Mori, Hirohito ^a   Kobara, Hideki ^a   Rafiq, Kazi ^a   Niki, Toshiro ^a   Hirashima, Mitsuomi ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Anti cancer therapy; Galectin 9; Recombinant galectin 9

Indexed keywords

ECALECTIN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL AGGREGATION; CHRONIC MYELOID LEUKEMIA; COLON ADENOCARCINOMA; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; METASTASIS; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; DENDRITIC CELLS; GALECTINS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE PROTEINS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84876727851     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214811307020006     Document Type: Article

References (81)

1. Gabius, HJ. Animal lectins. Eur J Biochem 1997; 243: 543-76.
2. Sharon N, Lis H. Lectins: From hemagglutinins to biological recognition molecules. A historical overview. Glycobiology 2004; 14: 53-62.
3. Feizi T. Progress in deciphering the information content of the 'glycome' - a crescendo in the closing years of the millennium. Glycoconj J 2000; 17: 553-65.
4. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: A family of animal - galactoside-binding lectins. Cell 1994; 76: 597-8.
5. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998; 273: 16976-84.
6. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu FT, et al. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem 2000; 275: 8355-60.
7. Matsumoto R, Hirashima M, Kita H, Gleich GJ. Biological activities of ecalectin: A novel eosinophil-activating factor. J Immunol 2002; 168: 1961-7.
8. Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, et al. Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002; 128: 42-50.
9. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, et al. Selective eosinophil adhesion to fibroblast via IFN-induced galectin-9. J Immunol 2002; 169: 5912-8.
10. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-52.
11. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol 2007; 250: 68-74.
12. Cooper DN. Galectinomics: Finding themes in complexity. Biochim Biophys Acta 2002; 1572: 198-202.
13. Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactoside-binding lectins: Structure, function and molecular evolution. Glycobiology 1993; 3:297-304.
14. Nagae M, Nishi N, Murata T, Usui T, Nakamura T, Wakatsuki S, et al. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J Biol Chem 2006; 281: 35884-93.
15. Nagae M, Nishi N, Nakamura-Tsuruta S, Hirabayashi J, Wakatsuki S, Kato R. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue. J Mol Biol 2008; 375: 119-35.
16. Bi S, Earl LA, Jacobs L, Baum LG. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem 2008; 283: 12248-58.
17. Li Y, Feng J, Geng S, Geng S, Wei H, Chen G, et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol Immunol 2011; 48: 670-7.
18. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: A search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232-54.
19. Mishra R, Grzybek M, Niki T, Hirashima M, Simons K. Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc Natl Acad Sci USA 2010; 107: 17633-8.
20. Ono K, Hattori H, Uemura K, Nakayama J, Ota H, Katsuyama T. Expression of Forssman antigen in human large intestine. J Histochem Cytochem 1994; 42: 659-65.
21. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007; 318: 1141-3.
22. Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 2002; 1572: 274-84.
23. Wada J, Oka K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a betagalactoside-binding lectin. J Clin Invest 1997; 99: 2452-61.
24. Kageshita T, Kashio Y, Yamauchi A, Seki M, Mohammad JA, Nishi N, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance Int J Cancer 2002; 99: 809-16.
25. Türeci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in Hodgkin's disease. J Biol Chem 1997; 272: 6416-22.
26. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997; 272: 6078-86.
27. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008; 127: 78-88.
28. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces apoptosis through the calcium-calpaincaspase-1 pathway. J Immunol 2003; 170: 3631-6.
29. Boenisch O, D'Addio F, Watanabe T, Elyaman W, Magee CN, Yeung MY, et al. TIM-3: A novel regulatory molecule of alloimmune activation. J Immunol 2010; 185: 5806-19.
30. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172-89.
31. Okudaira T, Hirashima M, Ishikawa C, Makishi S, Tomita M, Matsuda T, et al. A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines. Int J Cancer 2007; 120: 2251-61.
32. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21(10): 1258-65.
33. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol 2012; 143(1): 51-8.
34. Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji H, Nishi N, et al. Characterization of galectin-9-induced death of Jurkat T cells. J Biochem 2007; 141: 157-72.
35. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-41.
36. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Cur Top Microbiol 2011; 350: 1-15.
37. Oikawa T, Kamimura Y, Akiba H, Yagita H, Okumura K, Takahashi H, et al. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol 2006; 7: 4281-7.
38. Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. Immunol Rev 2009; 1: 259-70.
39. Moskophidis D, Lechner F, Pircher H, Zinkemagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-61.
40. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-13.
41. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-7.
42. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA 2008; 105: 15016-21.
43. Shapre, A.H., Butte, M.J., Oyama, S. Modulators of immunoinhibitory receptor PD-1, and methods of use thereof. US20130022629 (2013).
44. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-94.
45. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
46. Hirashima, M., Ito, A., Nishi, N., Yamauchi, A. Novel galectin 9 modification protein and use thereof. EP1736541 (2006).
47. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 17: 4501-10.
48. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011; 32(8): 345-9.
49. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012; 18(9): 1394-400.
50. Gabrilovich, DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
51. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13(9): 832-42.
52. Kuchroo, V., Anderson, A., Dardalhon, V. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof. EP2252319 (2010).
53. Langermann, S. Simultaneous inhibition of PD-L1/PD-L2. US20130017199 (2013).
54. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces apoptosis through the calcium-calpaincaspase-1 pathway. J Immunol 2003; 170: 3631-6.
55. Nishi, N., Hirashima, M., Yamauchi, A., Ito, A. Modified galectin 9 proteins and use thereof. US8268324 (2013).
56. Hirashima, M., Yamauchi, A., Kageshita, T., Nakamura, T., Nishi, N. Agent for detecting cancer's ability to metastasize. EP1331483 (2007).
57. Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010; 24: 843-50.
58. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, et al. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 2010; 8: 994-1001.
59. Makishi S, Okudaira T, Ishikawa C, Sawada S, Watanabe T, Hirashima M, et al. A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells. Br J Haematol 2008; 142: 583-94.
60. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114(8): 1545-52.
61. Monney, L., Freeman, G.J., Gaglia, J.L., Greenfield, E.A., Kuchroo, V.K. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule. US8101176 (2013).
62. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005; 11: 2962-8.
63. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008; 18: 735-44.
64. Wu FH, Yuan Y, Li D, Lei Z, Song CW, Liu YY, et al. Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol Rep 2010; 24: 693-9.
65. Guo Y, Ma J, Wang J, Che X, Narula J, Bigby M, et al. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994; 54: 1561-5.
66. Zawadzki V, Perschl A, Rosel M, Hekele A, Zoller M. Blockade of metastasis formation by CD44-receptor globulin. Int J Cancer 1998; 75: 919-24.
67. Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 2005; 175: 2974-81.
68. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008; 181: 7660-9.
69. Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol 2009; 130: 322-30.
70. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 119(13): 3064-72.
71. Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol 2012; 22(2): 127-1.
72. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009; 113: 1957-66.
73. Hirashima, M., Yamauchi, A., Kageshita, T., Nakamura, T., Nishi, N. Predicting agent for metastasis. US20090023143 (2009).
74. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 2012; 13(6): 2503-9.
75. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56(4): 1342-51.
76. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, Hirashima M, et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006; 6: 283.
77. Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010; 107: 20370-5.
78. Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J, Fiorini S, et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007; 13: 4993-5000.
79. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-46.
80. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Eqidio M, et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectinmediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006; 16(3): 210-220.
81. Woynarowska B, Skrincosky DM, Haag A, Sharma M, Matta K, Bernacki RJ. Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 1994; 269(36): 22797-803.